[company_age]1.0[/company_age][employees]2-10 employees[/employees][description]BioTryp Therapeutics is a biotechnology company developing a new class of small molecules that inhibit biofilm formation, offering a potential alternative to traditional antibiotic treatments. The company's technology targets bacterial biofilms, which are a major cause of chronic and recurrent infections. BioTryp's first indication is urinary tract infections (UTIs), which are the most common bacterial infection and the leading cause of bloodstream infections. The company's technology has the potential to revolutionize how UTIs are treated, as current front-line antibiotics are failing due to increasing widespread resistance.[/description][ps]Biofilm-inhibiting small molecules for UTIs[/ps]